Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVONASDAQ:AYTUNASDAQ:LMNLNASDAQ:LPTXNASDAQ:OTIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$3.05-1.0%$6.71$2.81▼$485.37$2.32M5.77605,359 shs367,767 shsAYTUAytu BioPharma$2.18+3.8%$1.69$0.95▼$2.96$19.57M0.05374,899 shs944,094 shsLMNLLiminal BioSciences$8.50$8.47$3.10▼$8.50$26.35M1.0363,470 shsN/ALPTXLeap Therapeutics$0.30+13.5%$0.38$0.22▼$4.79$12.30M-0.231.08 million shs1.12 million shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-26.14%-35.16%-86.72%-99.96%AYTUAytu BioPharma0.00%+5.00%+17.98%+75.00%-28.08%LMNLLiminal BioSciences0.00%0.00%0.00%0.00%0.00%LPTXLeap Therapeutics0.00%-31.16%-29.49%-14.26%-86.65%OTICOtonomy0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics2.6857 of 5 stars3.53.00.00.02.70.01.3AYTUAytu BioPharma3.5894 of 5 stars3.52.00.03.42.10.00.6LMNLLiminal BioSciencesN/AN/AN/AN/AN/AN/AN/AN/ALPTXLeap Therapeutics2.0336 of 5 stars3.02.00.00.03.00.01.3OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.007,181,539.34% UpsideAYTUAytu BioPharma 3.00Buy$12.00450.46% UpsideLMNLLiminal BioSciences 0.00N/AN/AN/ALPTXLeap Therapeutics 2.00Hold$3.381,036.75% UpsideOTICOtonomy 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OTIC, AYTU, LMNL, APVO, and LPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.75N/AN/A$65.21 per share0.05AYTUAytu BioPharma$81.66M0.24N/AN/A$4.64 per share0.47LMNLLiminal BioSciences$310K85.00N/AN/A$8.97 per share0.95LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)AYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%N/ALMNLLiminal BioSciences$380K$0.2929.31∞N/A248.35%-88.44%-64.15%N/ALPTXLeap Therapeutics-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ALatest OTIC, AYTU, LMNL, APVO, and LPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A0.670.67AYTUAytu BioPharma0.271.030.87LMNLLiminal BioSciences0.022.782.78LPTXLeap TherapeuticsN/A2.412.41OTICOtonomyN/A1.741.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%AYTUAytu BioPharma33.49%LMNLLiminal BioSciences0.66%LPTXLeap Therapeutics30.46%OTICOtonomy41.23%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%AYTUAytu BioPharma3.60%LMNLLiminal BioSciences2.20%LPTXLeap Therapeutics7.50%OTICOtonomy1.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50760,000755,000Not OptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableLMNLLiminal BioSciences2513.10 million3.04 millionNot OptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableOTICOtonomy5168.53 million67.78 millionOptionableOTIC, AYTU, LMNL, APVO, and LPTX HeadlinesRecent News About These CompaniesOtonomy's hearing loss drug shows no benefit in trial, tanking sharesSeptember 3, 2024 | pharmaphorum.comPTop 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023April 21, 2024 | straight.comSAllergic Contact Dermatitis and Topical AntibioticsSeptember 10, 2023 | medscape.comMHearing Loss in AdultsAugust 21, 2023 | nejm.orgNResearch PublicationsAugust 4, 2023 | slu.eduSManagement of Pediatric Otitis MediaMay 11, 2023 | medscape.comMHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRMay 8, 2023 | news.google.comNAlluvial Capital Management Q1 2023 Letter To Partners - Seeking AlphaApril 28, 2023 | news.google.comNVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital JournalApril 27, 2023 | news.google.comNHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRApril 25, 2023 | news.google.comNENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital JournalApril 24, 2023 | news.google.comNHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital JournalApril 11, 2023 | news.google.comNENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital JournalApril 10, 2023 | news.google.comN[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital JournalApril 10, 2023 | news.google.comNHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital JournalApril 3, 2023 | news.google.comNHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints NewsMarch 30, 2023 | news.google.comNAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints NewsMarch 30, 2023 | news.google.comNMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints NewsMarch 30, 2023 | news.google.comNBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints NewsMarch 30, 2023 | news.google.comNSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints NewsMarch 30, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingAnalyst Sees Meta Hitting $800: What May Lead Shares to New HighsBy Leo Miller | June 24, 2025View Analyst Sees Meta Hitting $800: What May Lead Shares to New HighsOTIC, AYTU, LMNL, APVO, and LPTX Company DescriptionsAptevo Therapeutics NASDAQ:APVO$3.05 -0.03 (-0.97%) As of 04:00 PM EasternAptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Aytu BioPharma NASDAQ:AYTU$2.18 +0.08 (+3.81%) As of 04:00 PM EasternAytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Liminal BioSciences NASDAQ:LMNLLiminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.Leap Therapeutics NASDAQ:LPTX$0.30 +0.04 (+13.49%) As of 04:00 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
